4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes
Background: Combination of insulin with oral antidiabetic drugs is a valid option, but oral combination therapy emerged as an alternative treatment in type 2 diabetes (T2DM). However, the effects on blood pressure (BP) and vascular function of such combination therapies is less clear. Methods: In t...
Main Authors: | Christian Ott, Susanne Jung, Agnes Bosch, Dennis Kannenkeril, Kristina Striepe, Roland Schmieder |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-02-01
|
Series: | Artery Research |
Online Access: | https://www.atlantis-press.com/article/125934393/view |
Similar Items
-
5.1 EFFECTS OF THE SGLT-2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION AND CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 DIABETES
by: Christian Ott, et al.
Published: (2017-12-01) -
Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure
by: Agnes Bosch, et al.
Published: (2023-06-01) -
Is vascular remodelling in patients with chronic heart failure exaggerated?
by: Robert Pietschner, et al.
Published: (2023-02-01) -
Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis
by: Mawadah Staef, et al.
Published: (2023-06-01) -
P142 EARLY VASCULAR PARAMETERS IN THE MICRO- AND MACROCIRCULATION IN TYPE 2 DIABETES
by: Christian Ott, et al.
Published: (2018-12-01)